Septerna (NASDAQ:SEPN) Rating Increased to Hold at Wall Street Zen

Key Points

• Septerna (NASDAQ:SEPN) has been upgraded from a "sell" to a "hold" rating by analysts at Wall Street Zen.
• Despite this upgrade, Septerna missed its quarterly earnings expectations, reporting a loss of ($0.56) earnings per share and only $0.12 million in revenue.
• The stock currently has an average rating of "Moderate Buy" among analysts, with a consensus target price of $26.75.

Wall Street Zen upgraded shares of Septerna (NASDAQ:SEPN - Free Report) from a sell rating to a hold rating in a report issued on Sunday.

Several other research firms have also recently weighed in on SEPN. HC Wainwright restated a "buy" rating and issued a $26.00 price objective on shares of Septerna in a research report on Thursday, August 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.75.

Septerna Price Performance

NASDAQ:SEPN traded up $0.26 during midday trading on Friday, reaching $16.26. The stock had a trading volume of 52,258 shares, compared to its average volume of 625,419. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The firm's fifty day simple moving average is $12.90 and its 200-day simple moving average is $9.83. The stock has a market capitalization of $724.74 million and a P/E ratio of -1.61.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, equities research analysts anticipate that Septerna will post -7.11 earnings per share for the current fiscal year.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock worth $107,000 after acquiring an additional 1,315 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Septerna during the fourth quarter worth $52,000. Rhumbline Advisers raised its position in Septerna by 16.6% during the first quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock worth $135,000 after acquiring an additional 3,323 shares in the last quarter. Deutsche Bank AG raised its position in Septerna by 53.3% during the first quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock worth $92,000 after acquiring an additional 5,549 shares in the last quarter. Finally, Rangeley Capital LLC raised its position in Septerna by 10.7% during the second quarter. Rangeley Capital LLC now owns 58,605 shares of the company's stock worth $619,000 after acquiring an additional 5,655 shares in the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.